AR125851A1 - Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas - Google Patents
Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticasInfo
- Publication number
- AR125851A1 AR125851A1 ARP220101261A ARP220101261A AR125851A1 AR 125851 A1 AR125851 A1 AR 125851A1 AR P220101261 A ARP220101261 A AR P220101261A AR P220101261 A ARP220101261 A AR P220101261A AR 125851 A1 AR125851 A1 AR 125851A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- cells
- car
- genetically modified
- focus
- Prior art date
Links
- 102100025221 CD70 antigen Human genes 0.000 title abstract 4
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 title abstract 4
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 230000003394 haemopoietic effect Effects 0.000 title 1
- 210000002865 immune cell Anatomy 0.000 title 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 abstract 6
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 5
- 201000005787 hematologic cancer Diseases 0.000 abstract 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 108091007741 Chimeric antigen receptor T cells Proteins 0.000 abstract 1
- 206010025327 Lymphopenia Diseases 0.000 abstract 1
- 102000043129 MHC class I family Human genes 0.000 abstract 1
- 108091054437 MHC class I family Proteins 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 230000003211 malignant effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4231—Cytokines
- A61K40/4232—Tumor necrosis factors [TNF] or CD70
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
Abstract
Las características de la presente divulgación se relacionan con composiciones que comprenden una población de células T modificadas genéticamente que transmiten un receptor de antígenos quiméricos (CAR) que une CD70, y métodos de uso de dicho tratamiento de células T y células B malignas. Reivindicación 1: Un método para tratar un cáncer hematopoyético, comprendiendo el método: (i) administrar a un paciente humano que tiene un cáncer hematopoyético, que opcionalmente es un cáncer hematopoyético CD70+, una o más dosis de un anticuerpo antiCD38, (ii) realizar un primer tratamiento de linfocitopenia al paciente humano después de la primera dosis del anticuerpo anti-CD38; y (iii) administrar al paciente humano una primera dosis de una población de linfocitos T genomodificados, que expresa un receptor quimérico para el antígeno (CAR) que se une a CD70 (linfocitos T-CAR anti-CD70) y es deficiente en la expresión de MHC Clase I. Reivindicación 90: Una población de linfocitos T-CAR anti-CD70 para su uso en un tratamiento de un cáncer hematopoyético, en donde los linfocitos T-CAR anti-CD70 se exponen en una cualquiera de las reivindicaciones 53 - 63 y 89 y el tratamiento se expone en una cualquiera de las reivindicaciones 1 - 52 y 64 - 88.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163187619P | 2021-05-12 | 2021-05-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125851A1 true AR125851A1 (es) | 2023-08-16 |
Family
ID=81749534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101261A AR125851A1 (es) | 2021-05-12 | 2022-05-12 | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20220387488A1 (es) |
| AR (1) | AR125851A1 (es) |
| TW (1) | TW202310870A (es) |
| WO (1) | WO2022238962A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023530408A (ja) | 2020-06-12 | 2023-07-18 | ンカルタ・インコーポレイテッド | Ｃｄ７０指向性がん免疫療法のための遺伝子修飾されたナチュラルキラー細胞 |
| DE102022132082B4 (de) | 2022-12-02 | 2024-08-08 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Verfahren zur Herstellung von genetisch transfizierten und mit Nanopartikeln und/oder einem zytotoxischen Stoff beladenen immunokompetenten Zellen sowie immunokompetente Zellen und medizinische Zusammensetzung. |
| DE102022132084B4 (de) | 2022-12-02 | 2024-08-22 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür |
| DE102022132083B4 (de) | 2022-12-02 | 2024-08-22 | Horia Hulubei National Institute for R & D in Physics and Nuclear Engineering (IFIN-HH) | Vorrichtung zum Porieren und zum Beladen von Zellen sowie Verfahren hierfür |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| BR0108545A (pt) | 2000-02-24 | 2004-06-29 | Xcyte Therapies Inc | Estimulação e concentração simultâneas das células |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| EP1720907B1 (en) | 2004-02-06 | 2015-04-08 | MorphoSys AG | Anti-cd38 human antibodies and uses therefor |
| ZA200709003B (en) | 2005-03-23 | 2009-05-27 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SI2580243T1 (sl) | 2010-06-09 | 2020-02-28 | Genmab A/S | Protitelesa proti humanemu CD38 |
| JOP20210044A1 (ar) | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| IL270415B2 (en) | 2017-05-12 | 2024-08-01 | Crispr Therapeutics Ag | Materials and methods for cell engineering and their uses in immuno-oncology |
| WO2019152742A1 (en) * | 2018-02-01 | 2019-08-08 | Pfizer Inc. | Chimeric antigen receptors targeting cd70 |
| CN112105420A (zh) | 2018-05-11 | 2020-12-18 | 克里斯珀医疗股份公司 | 用于治疗癌症的方法和组合物 |
| US20200073890A1 (en) | 2018-08-22 | 2020-03-05 | Three10 Solutions, Inc. | Intelligent search platforms |
| CN112969710A (zh) | 2018-09-14 | 2021-06-15 | 莱兰斯坦福初级大学评议会 | Spd-1变异体-fc融合蛋白 |
| WO2020058280A1 (en) | 2018-09-19 | 2020-03-26 | Handy Baby Products Limited | An apparatus for bathing an infant |
| MX2022000016A (es) | 2019-06-27 | 2022-02-24 | Crispr Therapeutics Ag | Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer. |
| KR20220100912A (ko) * | 2019-11-13 | 2022-07-18 | 크리스퍼 테라퓨틱스 아게 | Cd70을 표적화하는 유전자 조작된 t 세포를 사용하는 조혈 세포 악성종양에 대한 치료법 |
| CA3160423A1 (en) * | 2019-12-06 | 2021-06-10 | Fate Therapeutics, Inc. | Enhancement of ipsc-derived effector immune cell using small compounds |
-
2022
- 2022-05-12 AR ARP220101261A patent/AR125851A1/es unknown
- 2022-05-12 US US17/742,940 patent/US20220387488A1/en not_active Abandoned
- 2022-05-12 WO PCT/IB2022/054446 patent/WO2022238962A1/en active Application Filing
- 2022-05-12 TW TW111117915A patent/TW202310870A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202310870A (zh) | 2023-03-16 |
| US20220387488A1 (en) | 2022-12-08 |
| WO2022238962A1 (en) | 2022-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR125851A1 (es) | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en el tratamiento de neoplasias malignas hematopoyéticas | |
| MX2020013443A (es) | Receptores de antigeno quimerico de bcma y usos de los mismos. | |
| CL2020002075A1 (es) | Métodos para tratar el cáncer con anticuerpos anti-pd1. | |
| MX2022005815A (es) | Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70. | |
| UY38700A (es) | Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso | |
| DOP2018000212A (es) | Moléculas de unión a bcma y métodos de uso de las mismas | |
| CL2018002828A1 (es) | Anticuerpos biespecíficos contra el receptor de fc gamma cd25 para la reducción de células específicas de tumores. | |
| CO2022006014A2 (es) | Terapia de tumores sólidos cd70+ utilizando linfocitos t genomodificados dirigidos a cd70 referencia cruzada a solicitudes relacionadas | |
| CR20210042A (es) | RECEPTORES DE ANTÍGENOS QUIMÉRICOS DIRIGIDOS A BCMA Y MÉTODOS DE USO DE ESTOS (Divisional 2019-0050) | |
| CO2022000402A2 (es) | Uso de linfocitos t con receptor de antígeno quimérico e inhibidores de linfocitos citolíticos naturales para el tratamiento del cáncer | |
| PE20210517A1 (es) | Anticuerpos anti-hla-g y utilizacion de los mismos | |
| PE20211915A1 (es) | Receptores de antigenos quimericos dirigidos al antigeno de maduracion de celulas b y sus metodos de uso | |
| Asna et al. | Radiation therapy and immunotherapy—a potential combination in cancer treatment | |
| AR109707A1 (es) | Generación y uso en inmunoterapia adoptiva de células t de memoria tipo células madre | |
| MX2023006039A (es) | Celulas inmunes defectuosas para suv39h1. | |
| MX2022002244A (es) | Metodo para identificar respondedores a degradantes de smarca2/4. | |
| MX2022007833A (es) | Nuevos receptores de antigenos quimericos (car) especificos de mesotelina para inmunoterapia de cancer de tumores solidos. | |
| BR112022009204A2 (pt) | Terapia de carcinoma de células renais (rcc) usando células t geneticamente manipuladas visando cd70 | |
| MX2021013394A (es) | Métodos para administrar inmunoterapia con receptor de antígeno quimérico. | |
| CL2017001756A1 (es) | Régimen de dosificación para antagonistas de madcam. | |
| MX2021013960A (es) | Receptores de antígeno quimérico (car) de mesotelina y sus usos. | |
| BR112022009482A2 (pt) | Anticorpo monoclonal anti-b7-h3 e métodos de uso do mesmo | |
| CL2023000426A1 (es) | Neoantígenos ras y usos de los mismos | |
| BR112023024434A2 (pt) | Células hipoimunogênicas que compreendem hla-e ou hla-g geneticamente modificadas | |
| AR125852A1 (es) | Células inmunes modificadas genéticamente que se focalizan en cd70 para su uso en tratamiento de tumores sólidos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |